Effect of lovastatin on treatment of head and neck cancers
Phase 3
- Conditions
- Head and Neck Cancer.Malignant neoplasm of larynx, Malignant neoplasm of base of tongue, Malignant neoplasm of hypopharynxC32, C01,
- Registration Number
- IRCT2014121920368N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
inclusion criteria: pathologic evidence of locally advanced(T3,T4,N+) SCC of oral cavity,larynx and hypopharynx; being candidated for definitive chemoradiation; absence of underlying liver or kidney disease; not receiving any drug that interferes with metabolism of lovastatin.
Exclusion criteria: initiation of possible lovastatin side effects such as myopathy and liver toxicity; inability to swallow lovastatin tablets
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response rate. Timepoint: 3 months after treatment. Method of measurement: via CT scan.
- Secondary Outcome Measures
Name Time Method Acute side effects of treatment. Timepoint: last week of treatment. Method of measurement: physical examination and lab tests.